Virus-like particles: a new family of delivery systems

References

• Breitburd F, Coursaget P. Human papillomavirus vaccines. Cancer Biology 9, 431–445 (1999).
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad. Sci. USA. 89,12180–12184 (1992).
   PubMed Web of Science ®Google Scholar
• Suzich JA, Ghim SJ, Palmer-Hill FJ et al. Systemic immunization with papillomavirus Li protein completely prevents the development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA 92, 11553–11557 (1995).
   PubMed Web of Science ®Google Scholar
• Breitburd F, Kirnbauer R, Hubbert NL et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. ViroL 69,3959–3963 (1995).
   Google Scholar
• Greenstone HL, Nieland JD, de Visser KB et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA 95(4), 1800–1805 (1998).
   Google Scholar
• Schafer K, Muller M, Faath S et al. Immune response to human papillomavirus 16 LlE7 chimeric virus-like particles: induction of cytotoxic T-cells and specific tumor protection. Int. Cancer81(6), 881–888 (1999).
   Google Scholar
• Evans TG, Bonnez W, Rose RC et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. DA 183, 1485–1493 (2001).
   Google Scholar
• Harro CD, Pang YYS, Boden RBS et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 Li virus-like particle vaccine. J. Natl. Cancer Inst. 93(4), 284–292 (2001).
   Google Scholar
• Ball JM, Graham DY, Openkun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology 117,40–48 (1999).
   PubMed Web of Science ®Google Scholar
• Heermann KH, Gerlich WH. Molecular Biology of Hepatitis B virus. McLachlan A, CRC Press, Boca Raton, 109 (1991).
   Google Scholar
• Delpeyroux F, Chenciner N, Lim A et al. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science 233(4762), 472–475 (1986).
   PubMed Web of Science ®Google Scholar
• von Brunn A, Fruh K, Muller HM, Zentgraf HW, Bujard H. Epitopes of the human malaria parasite R falciparum carried on the surface of HBsAg particles elicit an immune response against the parasite. Vaccine 9(7), 477–484 (1991).
   Google Scholar
• Lee IH, Kim CH, Ryu WS. Presentation of the hydrophilic domains of hepatitis C viral E2 envelope glycoprotein on hepatitis B surface antigen particles. J. Med. Virol. 50(2), 145–151 (1996).
   Google Scholar
• Schlienger K, Mancini M, Riviere Y, Dormont D, Tiollais P, Michel ML. Human immunodeficiency virus Type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates. J. Virol. 66(4), 2570–2576 (1992).
   Google Scholar
• Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358(9297), 1927-1934 (2001).
   Google Scholar
• Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl. J. Med. 336(2), 86–91 (1997).
   Google Scholar
• Lalvani A, Moris P, Voss G et al. Potent induction of focused Thl-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J. Infect. Dis. 180(5), 1656–1664 (1999).
   Google Scholar
• Kingsman AJ, Burns NR, Layton GT, Adams SE. Yeast retrotransposon particles as antigen delivery systems. Ann. NY Acad. Sci. 754,202–213 (1995).
   Google Scholar
• Griffiths JC, Berrie EL, Holdsworth LN et al. Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant. J. Virol 65(1), 450–456 (1991).
   Google Scholar
• Harris SJ, Gearing AJ, Layton GT, Adams SE, Kingsman AJ. Enhanced proliferative cellular responses to HIV-1 V3 peptide and gP120 following immunization with V3:Ty virus-like particles. Immunology 77(3) 315–321 (1992).
   Google Scholar
• Mills KH, Kitchin PA, Mahon BP et al. HIV p24-specific helper T-cell clones from immunized primates recognize highly conserved regions of HIV-1. J. ImmunoL 144(5), 1677–1683 (1990).
   Google Scholar
• Layton GT, Harris SJ, Gearing AJ et al. Induction of HIV-specific cytotoxicT-lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J ImmunoL 151(2), 1097–1107 (1993).
   Google Scholar
• Layton GT, Harris SJ, Myhan J et al. Induction of single and dual cytotoxicT-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology 87(2) 171–178 (1996).
   Google Scholar
• Harris SJ, Woodrow SA, Gearing AJ, Adams SE, Kingsman AJ, Layton GT. The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice. Vaccine 14(10), 971–976 (1996).
   Google Scholar
• Sedlik C, Sarraseca J, Rueda P, Leclerc C, Casal I. Immunogenicity of poliovirus B and T-cell epitopes presented by hybrid porcine parvovirus particles. J. Gen. Virol. 76\(Pt 9), 2361–2368 (1995).
   Google Scholar
• Sedlik C, Saron M, Sarraseca J, Casal I, Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T-cells. Proc. Natl. Acad. Sci. USA 94(14), 7503–7508 (1997).
   Google Scholar
• Lo-Man R, Rueda P, Sedlik C, Deriaud E, Casal I, Leclerc C. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Thl immune response without adjuvant. Eur I Immunol. 28(4), 1401–1407 (1998).
   Google Scholar
• Sedlik C, Dadaglio G, Saron MF et al. In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.j Virol. 74 (13), 5769–5775 (2000).
   Google Scholar
• Martinez X, Regner M, Kovarik J et al. CD4-independent protective cytotoxic T-cells induced in early life by a nonreplicative delivery system based on virus-like particles. submitted (2002).
   Google Scholar
• Rueda P, Pominaya J, Langeveld JP, Bruschke C, Vela C, Casal JI. Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine 19(7-8), 726–734 (2000).
   Google Scholar
• Peng S, Frazer IH, Fernando GJ, Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology240(1), 147–157 (1998).
   Google Scholar
• Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T-cell epitopes. Virology273(2), 374–382 (2000).
   Google Scholar
• Nieland JD, Da Silva DM, Velders MP et al. Chimeric papillomavirus virus-like particles induce a murine self- antigen-specific protective and therapeutic antitumor immune response. J. Cell Biochem. 73(2), 145–152 (1999).
   Google Scholar
• Chackerian B, Lowy DR, Schiller JT. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc. Natl Acad. Sci. USA 96(5), 2373–2378 (1999).
   Google Scholar
• Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. j Clin. Invest. 108(3), 415–423 (2001).
   Google Scholar
• Sedlik C, Dridi A, Deriaud E et al. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses. J. Virol. 73(4), 2739–2744 (1999).
   Google Scholar
• Christensen ND, Cladel NM, Reed CA et al. Hybrid papillomavirus Li molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology291 (2), 324–334 (2001).
   Google Scholar
• Montefiori DC, Safrit JT, Lydy SL et al. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus Type 1 in rhesus macaques. J. Virol. 75(13), 5879–5890 (2001).
   Google Scholar
• Paliard X, Liu Y, Wagner R, Wolf H, Baenziger J, Walker CM. Priming of strong, broad and long-lived HIV Type 1 p55gag-specific CD8+ cytotoxic T-cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retrovir 16(3), 273–282 (2000).
   Google Scholar
• Liu XS, Liu WJ, Zhao KN, Liu YH, Leggatt G, Frazer IH. Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol. Cell Biol.. 80(1), 21–29 (2002).
   Google Scholar
• Liu XS, Abdul-Jabbar I, Qi YM, Frazer IH, Zhou J. Mucosa' immunisation with papillomavirus virus-like particles elicits systemic and mucosa' immunity in mice. Virology252(1), 39–45 (1998).
   Google Scholar
• Lehner T, Bergmeier LA, Panagiotidi C et al. Induction of mucosa' and systemic immunity to a recombinant simian immunodeficiency viral protein. Science 258(5086), 1365–1369 (1992).
   Google Scholar
• Lehner T, Brookes R, Panagiotidi C et al. T- and B-cell functions and epitope expression in nonhuman primates immunized with simian immunodeficiency virus antigen by the rectal route. Proc. Natl Acad. Sci. USA 90(18), 8638–8642 (1993).
   Google Scholar
• Bellone M, Iezzi G, Rovere P et al. Processing of engulfed apoptotic bodies yields T-cell epitopes. j Immunol. 159 (11), 5391–5399 (1997).
   Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (6671), 86–89 (1998).
   PubMed Web of Science ®Google Scholar
• Ronchetti A, Rovere P, Iezzi G et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells and cytokines. j Immunol. 163(1), 130–136 (1999).
   Google Scholar
• Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143(5), 1283–1288 (1976).
   Google Scholar
• Bevan MJ. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxicT-cell level during in vivo priming. Immunol. 117(6), 2233–2238 (1976).
   Google Scholar
• Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat. Rev Immunol. 1,128–135 (2001).
   Google Scholar
• Heath WR, Carbone FR. Cross- presentation, dendritic cells, tolerance and immunity. Ann. Rev Immunol. 19,47–64 (2001).
   PubMed Web of Science ®Google Scholar
• den Haan JM, Bevan MJ. Antigen presentation to CD8+ T-cells: cross-priming in infectious diseases. Curr. Opin. Immunol. 13(4), 437–441 (2001).
   Google Scholar
• Reimann J, Schirmbeck R. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunol. Rev 172,131–152 (1999).
   PubMed Web of Science ®Google Scholar
• Yrlid U, Svensson M, Johansson C, Wick MJ. Salmonella infection of bone marrow-derived macrophages and dendritic cells: influence on antigen presentation and initiating an immune response. FEMS Immunol. Med. Microbiol. 27(4), 313–320 (2000).
   Google Scholar
• Bohm W, Schirmbeck R, Elbe A et al. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T-lymphocytes in vivo. j Immunol. 155(7), 3313–3321 (1995).
   Google Scholar
• Schirmbeck R, Bohm W, Melber K, Reimann J. Processing of exogenous heat-aggregated (denatured) and particulate (native) hepatitis B surface antigen for class I-restricted epitope presentation. j Immunol. 155 (10), 4676–4684 (1995).
   Google Scholar
• Schirmbeck R, Melber K, Reimann J. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I- restricted epitope presentation. Eur. Immunol. 25(4), 1063–1070 (1995).
   Google Scholar
• Stober D, Trobonjaca Z, Reimann J, Schirmbeck R. Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T-cells. Eur. j Immunol. 32,1099–1108 (2002).
   PubMed Web of Science ®Google Scholar
• Schirmbeck R, Reimann J. 'Empty' Ld molecules capture peptides from endocytosed hepatitis B surface antigen particles for major histocompatibility complex class I- restricted presentation. Euij Immunol. 26(12), 2812–2822 (1996).
   Google Scholar
• Schirmbeck R, Thoma S, Reimann J. Processing of exogenous hepatitis B surface antigen particles for Ld- restricted epitope presentation depends on exogenous beta2-microglobulin. Eur. j Immunol. 27(12), 3471–3484 (1997).
   Google Scholar
• Kuhober A, Pudollek HP, Reifenberg K et al. DNA immunization induces antibody and cytotoxic T-cell responses to hepatitis B core antigen in H-2b mice. j Immunol. 156 (10), 3687–3695 (1996).
   Google Scholar
• Ruedl C, Storni T, Lechner F, Bachi T, Bachmann M. Cross-presentation of virus-like particles by skin-derived CD8-dendritic cells: a dispensable role for TAP. Eur. j Immunol. 32(3), 818–825 (2002).
   Google Scholar
• Storni T, Lechner F, Erdmann I et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T-cell responses after vaccination with virus-like particles. j Immunol. 168 (6), 2880–2886 (2002).
   Google Scholar
• Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-1 6 virus-like particles and induce epitope-specific human T-cell responses in vitro. Immunol. 166(10), 5917–5924 (2001).
   Google Scholar
• Lenz P, Day PM, Pang YY et al. Papillomavirus-like particles induce acute activation of dendritic cells. j Immunol. 166(9), 5346–5355 (2001).
   Google Scholar
• Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kest WM. Physical interaction of human papillomavirus virus-like particles with immune cells. Int. Immunol. 13(5), 633–641 (2001).
   Google Scholar
• Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA. Identification of the a6 integrin as a candidate receptor for papillomaviruses. j Virol. 71(3), 2449–2456 (1997).
   Google Scholar
• Joyce JG, Tung JS, Przysiecki CT et al. The Li major capsid protein of human papillomavirus Type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. j Biol. Chem. 274(9), 5810–5822 (1999).
   Google Scholar
• Moron G, Rueda P, Casal I, Leclerc C. CD8a CD 1 lb+ dendritic cells present exogenous virus-like particles (VLPs) to CD8+ T-cells and subsequently express CD8a and DEC205 molecules. j Exp. Med. 195(10), 1–14 (2002).
   Google Scholar
• Sigel LJ, Rock KL. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T-lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and - independent pathways of antigen presentation. I. Exp. Med. 192(8), 1143–1150 (2000).
   Google Scholar
• Da Silva DM, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the antitumor immune responses induced by chimeric human papillomavirus virus-like particles vaccines. Virology 290,350–360. (2001).
   PubMed Web of Science ®Google Scholar